Your session is about to expire
← Back to Search
DKd Regimen for Smoldering Multiple Myeloma
Study Summary
This trial is studying a combination of 3 drugs as a treatment for people with smoldering multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 3 trial • 498 Patients • NCT02136134Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any unmanaged ongoing illnesses.You have high levels of a protein called M-protein in your blood or a high percentage of plasma cells in your bone marrow.I cannot take certain medications due to adverse reactions.I don't have bone damage from cancer, except possibly one spot on my spine.The main goal of the study is to see if the disease is gone, so patients with very low levels of the disease in their blood may also be included in the study.My kidney function is normal, with creatinine below 2.0 mg/dL.My condition is confirmed as smoldering multiple myeloma.I am 18 years old or older.My organs and bone marrow are working well.I have a serious heart condition.I have had treatment for smoldering multiple myeloma, with some exceptions.I have COPD or severe asthma.I am HIV positive or have an active hepatitis B infection.I can take care of myself but might not be able to do heavy physical work.I am classified as high-risk for smoldering multiple myeloma.My blood pressure or diabetes is not well-managed.Your blood calcium level is below a certain number.Your hemoglobin level is higher than 10 grams per deciliter.
- Group 1: Arm 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what maladies is Daratumumab commonly administered?
"Daratumumab can be administered to patients suffering from ophthalmia, sympathetic problems, branch retinal vein occlusions and macular edema."
Is recruitment still available for this research endeavor?
"Indeed, information on clinicaltrials.gov reveals that this experiment is still enrolling participants. It was initially uploaded on October 31st 2022 and most recently edited November 19th of the same year. 59 individuals are being sought for participation at a single medical facility."
Are there any other research endeavors that have utilized Daratumumab?
"At the moment, there are 617 Daratumumab-related clinical trials in progress. Of these studies, 151 have entered Phase 3 and most of them take place in Joliet, Illinois. However, across the United States alone there are over 20 thousand locations running clinical trials related to this medication."
How many people have been accepted as participants in this clinical trial?
"Affirmative. According to the details provided on clinicaltrials.gov, this medical research is still welcoming participants; it was first listed on October 31st 2022 and last revised November 19th of that same year. The study requires 59 volunteers who will be evaluated at one specific site."
Has the FDA sanctioned Daratumumab for public use?
"Based on the limited knowledge of this drug, our team at Power awarded Daratumumab a 2 out of 3 for safety. This is because while there are some studies that have demonstrated its security, it has yet to be shown effective in clinical trials."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger